We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CU6 market cap is 1.31B. The company's latest EPS is AUD -0.1362 and P/E is -31.06.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 3.29M | 6.46M | 9.8M | 11.51M |
| Operating Income | 0 | -10.22M | -23.83M | -26.36M | -44.8M |
| Net Income | 0 | -10.22M | -23.76M | -24.6M | -42.32M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 113.48M | 22.61M | 99.82M | 76.9M | 154.63M |
| Total Liabilities | 2.02M | 2.34M | 7.59M | 7.72M | 8.33M |
| Total Equity | 111.46M | 20.28M | 92.24M | 69.18M | 146.3M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | N/A | -7.68M | -13.31M | -27.5M | -43.24M |
| Investing | N/A | -60k | -26.71M | 3.15M | -55.31M |
| Financing | N/A | 10.92M | 86.93M | 232k | 115.21M |
| Market Cap | 1.31B |
| Price to Earnings Ratio | -31.06 |
| Price to Sales Ratio | 114.32 |
| Price to Cash Ratio | 27.45 |
| Price to Book Ratio | 8.99 |
| Dividend Yield | - |
| Shares Outstanding | 310.78M |
| Average Volume (1 week) | 3.92M |
| Average Volume (1 Month) | 2.04M |
| 52 Week Change | 129.89% |
| 52 Week High | 8.975 |
| 52 Week Low | 1.80 |
| Spread (Intraday) | 0.07 (1.65%) |
| Company Name | Clarity Pharmaceuticals Ltd |
| Address |
national innovation centre, suite 212a, 2-4 cornwallis stre bathurst, new south wales |
| Website | https:// |
| Industry | drug & proprietary stores (5912) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
